High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097

Molecular Oncology

Volumn 5, Issue 3, 2011, Pages 292-301

  He, Wei ^a   Luistro, Leopoldo ^a   Carvajal, Daisy ^a   Smith, Melissa ^a   Nevins, Tom ^a   Yin, Xuefeng ^a   Cai, James ^a   Higgins, Brian ^a   Kolinsky, Kenneth ^a   Rizzo, Christine ^a   Packman, Kathryn ^a   Heimbrook, David ^a   Boylan, John F ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

IL6; IL8; Notch; RO4929097; secretase

Indexed keywords

GAMMA SECRETASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; NOTCH RECEPTOR; RO 4929097; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; PATIENT SELECTION; PRIORITY JOURNAL; TISSUE CULTURE; TREATMENT OUTCOME; TUMOR XENOGRAFT; VALIDATION STUDY; XENOGRAFT;

EID: 79957443831     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.01.001     Document Type: Article

References (31)

1. Baumgart A., et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 2010, 70:5368-5378.
2. Borg S.A., Kerry K.E., Royds J.A., Battersby R.D., Jones T.H. Correlation of VEGF production with IL1α and IL6 secretion by human pituitary adenoma cells. Eur. J. Endocrinol. 2005, 152:293-300.
3. Brat D.J., Bellail A.C., Van Meir E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005, 7:122-133.
4. Carmeliet P., DeSmet F., Loges S., Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat. Rev. Clin. Oncol. 2009, 6:315-326.
5. Copeland N.G., Jenkins N.A. Deciphering the genetic landscape of cancer-from genes to pathways. Trends Genet. 2009, 25:455-462.
6. Dang T.P., Gazdar A.F., Virmani A.K., Sepetavec T., Hande K.R., Minna J.D., Roberts J.R., Carbone D.P. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J. Natl. Cancer Inst. 2000, 92:1355-1357.
7. Dufraine J., Funahashi Y., Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008, 27:5132-5137.
8. D'Souza B., Miyamoto A., Weinmaster G. The many facets of notch ligands. Oncogene 2008, 27:5148-5167.
9. Fortini M.E. Notch signaling: the core pathway and its posttranslational regulation. Dev. Cell. 2009, 16:633-647.
10. Grötzinger J., Kurapkat G., Wollmer A., Kalai M., Rose-John S. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins 1997, 27(1):96-109.
11. Hong D.S., Angelo L.S., Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007, 110:1911-1928.
12. Lee J., Cacalano G., Camerato T., Toy K., Moore M.W. WoodWI. Chemokine binding and activities mediated by the mouse IL-8 receptor. J. Immunol. 1995, 155(4):2158-2164.
13. Levina V., Su Y., Nolen B., Liu X., Gordin Y., Lee M., Lokshin A., Gorelik E. Chemotherapeutic drugs and human tumor cells cytokine network. Int. J. Cancer 2008, 123:2031-2040.
14. Li J., Harris A.L. Crosstalk of VEGF and Notch pathways in tumor angiogenesis: therapeutic implications. Front. Biosci. 2009, 14:3094-3110.
15. Li Q.J., Yao M., Wong W., Parpura V., Martins-Green M. The N- and C-terminal peptides of hIL8/CXCL8 are ligands for hCXCR1 and hCXCR2. FASEB J. 2004, 18(6):776-778.
16. Liu Q., Li G., Li R., Shen J., He Q., Deng L., Zhang C., Zhang J. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J. Neurooncol April 2, 2010, (published online ahead of print).
17. Luistro L., et al. Preclinical profile of a potent γ-secretase inhibitor targeting Notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res. 2009, 69:7672-7680.
18. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates vascular endothelial growth factor expression and autocrine activation of VEGFR2 in endothelial cells by activating NFκB through the CBM (Carma3/Bcl10/Malt1) complex. J. Biol. Chem. 2009, 284:6038-6042.
19. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophy Acta 2010, 1805:105-117.
20. Mizukami Y., Jo W.S., Duerr E.M., Gala M., Li J., Zhang X., Zimmer M.A., Iliopoulos O., Zukerberg L.R., Kohgo Y., Lynch M.P., Rueda B.R., Chung D.C. Induction of interleukin-8 preserves the angiogenic response in HIF-1-deficient colon cancer cells. Nat. Med. 2005, 11:992-997.
21. Noguera-Troise I., et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444(7122):1032-1037.
22. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6 secretion by human ovarian cells, is a potent proangiogenic cytokine. Cancer Res. 2005, 65:10794-10800.
23. Phng L.K., Gerhardt H. Angiogenesis: a team effort coordinated by Notch. Dev. Cell. 2009, 16:196-208.
24. Ridgway J., et al. Inhibition of Dll4 signaling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444(7122):1083-1087.
25. Simonet W.S., Hughes T.M., Nguyen H.Q., Trebasky L.D., Danilenko D.M., Medlock E.S. Long-term impaired neutrophil migration in mice overexpressing human interleukin-8. J. Clin. Invest. 1994, 94(3):1310-1319.
26. Smith D.R., Polverini P.J., Kunkel S.L., Orringer M.B., Whyte R.I., Burdick M.D., Wilke C.A., Strieter R.M. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med. 1994, 179:51409-51415.
27. Tien A., Rajan A., Bellen H.J. A Notch updated. J. Cell Biol. 2009, 184:621-629.
28. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 1990, 8:253-278.
29. Vecchiarelli-Federico L.M., Cervi D., Haeri M., Li Y., Nagy A., Ben-David Y. Vascular endothelial growth factor-a positive and negative regulator of tumor growth. Cancer Res. 2010, 70:863-867.
30. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008, 14:6735-6741.
31. Wu Y., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464:1052-1059.